Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 169

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 169
---
) from available-for-sale debt securities. 

83

The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):December 31, 2024Amortized CostFair ValueWithin one year$127,296 $127,331 After one year through five years12,937 12,928      Total$140,233 $140,259 The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):Less than 12 months12 months or greaterTotalGrossUnrealizedLossesEstimatedFair ValueGrossUnrealizedLossesEstimatedFair ValueGrossUnrealizedLossesEstimatedFair ValueDecember 31, 2024Certificates of Deposit$(4)$6,195 $— $— $(4)$6,195 Corporate notes/bonds(1)866 (7)3,026 (8)3,892 Commercial paper(6)9,344 — — (6)9,344 U.S. Treasuries(4)29,965 (9)4,764 (13)34,729      Total$(15)$46,370 $(16)$7,790 $(31)$54,160 December 31, 2023Certificates of Deposit$(1)$4,175 $— $— $(1)$4,175 Corporate notes/bonds(1)1,410 (1)1,447 (2)2,857 Commercial paper(4)10,222 — — (4)10,222 Municipal bonds(4)1,004 — — (4)1,004 U.S. Treasuries— 998 (3)1,502 (3)2,500      Total$(10)$17,809 $(4)$2,949 $(14)$20,758 Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 45 securities which were in an unrealized loss position with a total of $0.03 million unrealized losses as of December 31, 2024. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes